The Conversation (0)
July 31, 2025
INN Article Notification
29 August 2025
FY25 Preliminary Results Summary and Company Update
Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
29 August 2025
Appendix 4E
Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Activities Report
Cardiex Limited (CDX:AU) has announced June Quarterly Activities ReportDownload the PDF here. Keep Reading...
24 June 2025
Results of Entitlement Offer
Cardiex Limited (CDX:AU) has announced Results of Entitlement OfferDownload the PDF here. Keep Reading...
05 June 2025
Offer Booklet - Non-Renounceable Entitlement Offer
Cardiex Limited (CDX:AU) has announced Offer Booklet - Non-Renounceable Entitlement OfferDownload the PDF here. Keep Reading...
08 April
Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio
AI developer Anthropic is acquiring New York-based biotech startup Coefficient Bio for approximately US$400 million, according to The Information.Founded just last fall and operating largely in stealth, Coefficient Bio will be absorbed directly into Anthropic’s healthcare life sciences... Keep Reading...
07 April
Lexaria Applauds Eli Lilly's Foundayo Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...
07 April
Lexaria Applauds Eli Lilly's Foundayo Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...
25 February
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen... Keep Reading...
10 February
5 Small-cap Biotech ETFs to Watch
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
10 February
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00